Abstract: Malignant tumors have gradually become the most common chronic non-communicable diseases in China. Recent research has indicated that malignant tumors are closely associated with hyperglycemia and diabetes. On one hand, hyperglycemia and diabetes increased the morbidity of many malignant tumors, and are related to their poor prognosis. On the other hand, some tumors can also cause hyperglycemia and diabetes. In addition, hyperglycemia and diabetes may occur during the treatment of malignant tumor. These are all described as tumor-associated hyperglycemia. However there is no relevant guidance for clinical diagnosis, treatment and management. Experts from the Onco-endocrinology Society of Chinese Anti-Cancer Association and Onco- endocrinology Society of ChongQing Integrative Medicine Association summarized the research progress of tumor-associated hyperglycemia, aimed to transmit recent important progress and guide clinical practice. This guideline mainly covered the overview of tumor-associated hyperglycemia, clinical diagnosis, treatment and long-term follow-up management. This guideline may help clinicians to standardize the management of patients with tumor-associated hyperglycemia, and improve the clinical outcomes of patients with tumor-associated hyperglycemia in China.

Key words:  Tumor-associated hyperglycemia, Management, Guidelines